

Australia's SpeeDx expands portfolio of SARS-CoV-2 genotyping reagents

07 October 2021 | News

For detecting Lambda variant of interest

SpeeDx., based in Australia, continues to expand its line of research reagents for the analysis of COVID-19 variants. This product line now includes an essential characteristic of mutation linked to the Lambda variant of interest of SARS-CoV-2.

The Plex Prime® Genotyping Product Line SARS-CoV2 has grown rapidly since its launch in July, using the company's unique universal substrate approach and patented multiplexing technology.

This product line can be used independently or in combination to support efforts to research and monitor laboratories for SARS-CoV-2 variants of essential interest or concern.

The Plex Prime® SARS-CoV-2 L452Q Lambda reagent is a single-well mix designed to detect the L452Q mutation of the SARS-CoV-2 Spike protein found in the C.37 (Lambda) variant of interest, in addition to a target RdRp gene for SARS-CoV-2.

This reagent, the third product in our Plex Prime® SARS-CoV-2 genotyping portfolio, can be used as a stand-alone reflex reagent or in combination with the Plex Prime® SARS-CoV-2 Alpha / Beta / Gamma +reagents, and / or Plex Prime® P681R Delta.